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Background: The risk of multiple sclerosis (MS) increases with increasing latitude. Taking into consideration that
Norway has a large latitude range, a south-to-north gradient would be expected. However, previous studies have
reported an uneven distribution of the disease in Norway, with a relatively low prevalence in the most northern
parts of the country.
We describe the incidence and prevalence of MS in a county in the north of Norway over a period of 40 years.
Methods: All patients with MS living in Nordland County in the period 1970–2010 were identified by reviewing
hospital charts. The patients were included if they met the criteria of definitive or probable MS according to Poser
[Ann Neurol 13:227-231, 1983] or MS according to McDonalds [Ann Neurol 50:121-127, 2001]. Point prevalence at
the beginning of the decades was calculated. The average annual incidence was calculated for 5-year periods.
Results: The total crude prevalence on January 1, 2010 was 182.4 per 100 000. The annual incidence continuously
increased from 0.7 per 100 000 in 1970 – 1974 to 10.1 per 100,000 in 2005 – 2009. The time delay from the first
symptom to diagnosis was stable from 1975 to 2010. The proportion of primary progressive MS in the prevalence
numbers was 38.2% in 1980, and decreases continuously, to 18.6% in 2010. The female to male prevalence ratio has
been stable since 1990 at 2.2 to 1.
Conclusion: The prevalence and the incidence of MS have steadily increased over a 40 year period. Nordland
County is a high-risk area for MS.
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Multiple sclerosis (MS) is a chronic inflammatory de-
myelinating disease in the central nervous system with
unknown aetiology. A latitude dependent gradient in the
occurrence has been shown in many countries and re-
gions. The risk of MS is increasing from south to north
in Europe, North America and Japan [1-4] on the north-
ern hemisphere, and from north so south in Australia
and New Zealand [5,6] on the southern hemisphere. In
general, the risk increases with increasing distance from
the equator [7]. Norway has a long and narrow land-
scape, with the mainland stretching from 57° N to 71° N,* Correspondence: espen.benjaminsen@nlsh.no
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article, unless otherwise stated.and a similar north–south gradient of the MS prevalence
would thus be expected. However, previous studies have
shown an uneven distribution in Norway, with a rela-
tively low prevalence in the most northern parts of the
country (Figure 1) [8-15]. This variation has been attrib-
uted to specific genetic and environmental factors. There
is accumulating evidence that hypovitaminosis D is an
important risk factor for MS [16], and it has been sug-
gested that low sun exposure, and thereby reduced pro-
duction of cutaneous vitamin D, in the high latitudes
could be one cause of the observed increase in these areas.
The paradoxically low occurrence of MS in the north of
Norway could then be explained by high dietary intake of
vitamin D through fish consumption [17,18]. The genetics
of the indigenous population of the far north could also be
an explanation for the reversed gradient observed. Theentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Prevalence of MS in Norwegian counties.
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protected against MS. The first known appearance
among them is registered as late as the 1990s [10]. MS is
associated with the human leukocyte antigen DRB1*15-
DQB1*06, and the Sami have a low frequency of this
haplotype [19].
To contribute to a more precise knowledge of the distri-
bution of MS, we assess the prevalence and incidence of
multiple sclerosis in Nordland County in the period 1970
to 2010. Interim data published in Norwegian in 2005,
showed a prevalence of 105.6 per 100 000 at December 31,
1999 [20]. All data from this survey was reexamined. We
describe trends in the occurrence over four decades in an
area with a stable and relatively homogeneous population.
Methods
This is a retrospective cross-sectional epidemiological
study.
Geographical area
Nordland is in the northern part of Norway, situated
between latitude 64°56’ N and 69°20’ N. The Arctic Cir-
cle at 66°33’ N is running through the county in be-
tween Mo i Rana and Bodø, the two largest cities. The
county, covering a total area of 38456 km2, includes the
regions of Helgeland, Salten, Ofoten, and the islands of
Lofoten and Vesterålen. The population at risk at January1, 2010 was 236 271 (118537 men, 117734 women). The
population was 243 179 in 1970, indicating an average
yearly reduction in the population of 0.07% in the period.
The only neurological department is at the Nordland
Hospital in Bodø, serving both outpatients and hospita-
lised patients. The department was founded in 1973, but
a neurologist was at place a year earlier, and MS patients
are registered from 1970. There are neurological out-
patient services at the hospitals in Mosjøen (Helgeland)
and Stokmarknes (Vesterålen).
Case ascertainment
All patient with the diagnoses of MS treated at the hos-
pital in Bodø were identified by searching for the diagnosis
according to ICD 8 (340.08), ICD 9 (340) and ICD 10
(G35) in the hospital’s medical files. In addition to the files
of Nordland Hospital in Bodø, we searched the files from
the hospitals in Mosjøen and Stokmarknes. We also re-
quested for files and cases from the neurological depart-
ment in Namsos in the neighbor county to the south, and
from the two nearest university hospitals, the University
Hospital of North Norway in Tromsø in the neighbor
county to the north and St. Olavs Hospital in Trondheim
to the south. The records were examined and the diagno-
ses were confirmed by a neurologist. Patients were in-
cluded if they satisfied the criteria for clinically definite
MS, laboratory supported definite MS, clinically probably
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scribed by Poser in 1983 [21] or MS after the criteria of
McDonald from 2001 [22]. Cases that were misclassified
or did not fulfill these criteria were excluded. Some pa-
tients had been treated at more than one hospital. By
combining the files from different hospitals, additional in-
formation was obtained, and the diagnoses could be
reconfirmed. We classified the cases as primary progres-
sive MS (PPMS) or relapsing remitting MS (RRMS) course
at onset. The stipulation of the year of the first symptom
was based partly on older records of findings and symp-
toms in the files, and partly on the written information of
the patients’ later recollection of former symptoms.
Statistics
We have used the time of diagnosis as starting point for
the epidemiological calculations. The point prevalence
rate was defined as the proportion of the population in
Nordland County with definitive or probable MS accord-
ing to Poser or MS according to McDonalds at a speci-
fied time point. We calculated the point prevalence per
100 000 inhabitants for January 1, in 1980, 1990, 2000
and in 2010. The incidence rate was defined as the pro-
portion of the population in Nordland County who got
definitive or probable MS according to Poser or MS ac-
cording to McDonalds during a specified time period.
The average annual incidence was calculated for 5-year
periods. Both prevalence and incidence were calculated
for females and males separately, and we calculated the
female to male (f/m) sex ratio.
We calculated the mean and median time delay from
first symptom to diagnosis for each 5-year period. Data
of population by age and gender were obtained from
Statistics Norway [23]. Data considering the Sami popu-
lation was obtained from the website of Sametinget, the
Sami Parliament [24]. A Poisson distribution of the dis-
ease was assumed, and the 95% confidence interval (CI)
for both the prevalence and the incidence was calcu-
lated. The age adjusted prevalence and incidence were
calculated by the use of data from a standard European
population [25]. A chi squared test was used to give a
statistical description of the change of the proportion of
PPMS in the prevalence rate over time. Statistical ana-
lyses were performed by the use of StatXact version 10
for Windows (Cytel Software, Cambridge, MA) and
Microsoft Office Exel for Windows 7.
Ethical approval
The study was approved by the Regional Committee for
Medical and Health Research Ethics (REK Nord).
Results
We identified a total of 533 persons with definitive or
probable MS. Ten persons had got the diagnoses before1970, while 26 had received the diagnosis elsewhere and
moved to the county. Twenty-two subjects diagnosed
with MS had left the county, five had moved both to
and from the county. Eighty patients had died during
the period. The number of new cases diagnosed in the
county is shown in Figure 2. In 7 cases the time of the
first symptom could not be determined, 4 of these pa-
tients had got the diagnosis before 1970, 1 had got the
diagnosis in the period 1975–79, 1 in the period 1985–
89 and 1 in the period 90–94.
The number of persons with MS in the county in the
present study differs slightly from the data previous pub-
lished for the period 1970–2000 (20). Three cases were
reclassified not to be MS. Seven persons received the
diagnosis per letter after they had performed MRI at
other hospitals, and were not registered in our files until
they were treated in our department years later. Nine-
teen patients had been treated at the hospital in
Mosjøen, a hospital that had not been included in the
previous study. In the present study a total of 36 patients
were identified exclusively outside our hospital.
On January 1, 2000 there were 158 persons diagnosed
with MS that had not been examined with MRI. In all of
the patients diagnosed during the period 2000–2009 an
MRI had been performed.Prevalence
At January 1, 2010, 431 persons had definitive or prob-
able MS. The crude prevalence was 182.4 per 100 000.
The age adjusted prevalence was slightly lower, 174.4
per 100 000. The crude prevalence among women was
249.7 per 100 000 and among men 115.6 per 100 000.
Table 1 shows the crude prevalence and prevalence by
gender at the beginning of the decades. The prevalence
increased significantly from 1970 to 2010, p < 0.001.
Figure 3 shows the age specific prevalence rates ac-
cording to gender. The mean age of the MS patients in-
creased continuously, and was 51.2 years in 2010. The
female to male (f/m) prevalence ratio was 3.3 in 1980,
but was then stable at 2.2 from 1990 to 2010 (Table 2).
The proportion of PPMS in the prevalence numbers
was 38.2% in 1980, and decreases continuously, to 18.6%
in 2010 (Table 3). This is a statistical significant decline,
p = 0.002.Incidence
In the period 1970–2009 there were 497 persons who
received the diagnosis while living in the county. The in-
cidence was continuously increasing in the whole period,
and the yearly average incidence was 10.1 per 100 000 in
2005–2009. This was a significant increase from the
period 2000–2004, p = 0.031. The increase was also sig-
nificant from 1985–1989 to 1995–1999, p = 0.031. The
Figure 2 Number of new cases diagnosed per year 1970 – 2009.
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are shown in Table 4.
The mean age at the time of the diagnosis was stable
during the whole period, and the time from first symp-
tom to diagnosis was stable from 1975 to 2010 both in
terms of mean and median (Table 5).
The f/m ratio was 2.1 in the period 1975–1979 and 2.2
in the period 2005–2009 (Table 6).
In the incidence numbers the proportion of PPMS de-
creased from 33.3% in 1970–1974 to 20.6% in 1990–
1994. The proportion of PPMS was 21.8% of the new
cases in the period 2005–2009, and had been quite
stable from 1990 (Table 7).
Discussion
The prevalence of MS has increased steadily in Nordland
County during the last four decades. One contribution to
this increase is the accumulation of cases. A total of 497
new patients were diagnosed, while only 80 died. The ac-
cumulation is reflected in the mean age, which increased
from 45 to 51 years from 1980 to 2010. However, the main
reason for the increase of prevalence is an increase of the
incidence. The incidence was 0.7 per 100 000 in 1970–
1974, and remained less than 5 per 100 000 until 1985. It
reached 7 per 100 000 during 1995–1999, and was over 10
per 100 000 in the last period 2005–2010 (Table 4).
The Poser criteria were introduced in 1983, and we
find a marked increase in new cases in 1983 and 1984Table 1 Prevalence of MS in Nordland County at the beginnin
Total
Year Population at risk Cases Prevalence (
1980 243 808 34 13.9 (9.7-19.5
1990 239 532 152 63.5 (53.8-74.
2000 239 109 275 115.0 (101.8-1
2010 236 271 431 182.4 (165.6-2compared with previous years. In 2001 the diagnostic
criteria of McDonald were established, again followed by
an increase of diagnosed cases in our county. The new
criteria probably made it easier to conclude in the diag-
nostic work-up. Also, following the introduction of new
criteria more focus could have been put on the disease,
and thereby increasing the diagnostic sensitivity. Because
of the long time span of our study, we have included
cases fulfilling the criteria either according to Poser or
according to McDonald, or both. Other Norwegian stud-
ies were only Poser criteria are applied report increasing
incidence [11,13]. Studies that compare the figures when
Poser and McDonalds criteria are applied on the same
population have found only small differences in the
prevalence [26,27].
Magnetic resonance imaging (MRI) has become an im-
portant tool in the diagnostic work up of MS. The role
of MRI in the study of MS-epidemiology and changes
over time is an interesting but difficult issue. The first
MRI scanner in Nordland was set up in autumn 2000.
Prior to this, MRI was available in neighbouring regions,
from 1986 in Trondheim and from 1991 in Tromsø. At
prevalence day January 1, 2010 there were 5 MRI scan-
ners in the county. Monosymptomatic cases and clinical
isolated syndromes will not necessarily fulfill the criteria
after Poser. If dissemination in time and space is demon-
strated with MRI changes the diagnosis can be given
with the McDonalds criteria. On January 1, 2000 thereg of 4 decades
95% CI) Age adjusted prevalence Mean age (SD)
) 16.9 45.3 (10.7)
4) 70.5 45.4 (12.0)
29.4) 117.9 48.1 (11.6)
00.5) 174.4 51.2 (12.2)
Figure 3 Age-specific prevalence rates by gender on January 1, 2010.
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formed MRI. All of the 207 patients diagnosed in the
period 2000–2009 had performed a MRI scan. Of the
163 with RRMS, 38 were monosymptomatic at the time
of diagnosis. The diagnosis was based on dissemination
in time demonstrated on MRI. However, 21 of these 38
had a new clinical attack before 2010, thereby fulfilling
the criteria for clinically definite MS after Poser as well.
If those 17 not fulfilling the criteria for clinical MS after
Poser were excluded, the prevalence rate at January 1,
2010 would drop from 182.4 to 175.2. This is a reduc-
tion of 3.9%. Although MRI findings are not included in
the Poser criteria, the use of MRI will most likely in-
crease the diagnostic sensitivity. Our experience is that if
there are pathological findings on an MRI scan, more
emphasis is put in the patient interview to reveal MS
manifestations in the past. A patient with light symp-
toms or mainly sensory symptoms could be more easily
diagnosed with this technique. On the other hand, MRI
scans will rule out cases where other diagnoses are more
likely.
Another potential contributor to increased diagnostics
is the immunomodulatory treatment for MS that was
available in clinical practice from the second half of the
90’s. It may have urged the necessity of diagnosing the
condition, and increased the diagnostic sensitivity.
In the present study we report a steady age at time of
diagnosis (Table 5). The mean age at onset, that is the timeTable 2 Gender specific prevalences
Women Men F/M sex ratio
Year Cases Prevalence Cases Prevalence
1980 26 21.6 8 6.5 3.3
1990 104 87.3 48 39.9 2.2
2000 189 158.1 86 71.9 2.2
2010 294 249.7 137 115.6 2.2of diagnosis, was about 40 years during the whole period.
We also report a steady time delay from the first symptom
to the diagnosis. The mean time delay was 5.0 years in
2005–2009. This may intuitively seem a bit high, but is in
accordance with other Norwegian studies. The results
from a study in Oslo [11], also applying “time of diagnosis”
as onset, are almost identical to ours. In 1972–1985 a
mean age at onset of 38.7 year, and a mean time from the
first symptom to the diagnosis of 5.9 year were found. This
changed only slightly until 1985–1999, where the mean
age at onset was 38.1, and the mean time from the first
symptom to diagnosis was 5.2 year [11]. Other studies,
which use first symptom as time of inclusion, report a
marked decrease in time delay [12,13]. If we had used the
“time of the first symptom” as starting point for the calcu-
lation, the mean time delay would have been 1.1 year and
the median time delay 1 year in the period 2005–09. This
is however an artificial time decline. When the “time of
first symptom” is used, everyone included from the latest
year would, by definition, have a time delay less than one
year. We think that if increased incidence was only due to
improved and faster diagnostic work up, the time delay
from the first symptom to the diagnosis would be ex-
pected to decline.
Our findings show that the female to male (f/m) sex
ratio has been stable over time. Based on the prevalence
numbers it was 2.2 in 2010 which is unchanged from
1990 (Table 2). The f/m sex ratio based on incidenceTable 3 Distribution of the prevalence of PPMS and RRMS
course at onset
Year PPMS, % (n) RRMS, % (n) Unknown, % (n)
1980 38.2 (13) 52.9 (18) 8.8 (3)
1990 27.0 (41) 65.1 (99) 7.9 (12)
2000 21.5 (59) 76.0 (209) 3.3 (9)
2010 18.6 (80) 80.0 (345) 1.4 (6)
Table 4 Yearly average incidence of MS in 5-year periods
Total
Years Average population Cases Incidence (95% CI) Age-adjusted incidence
1970-1974 241867 9 0.7 (0.34-1.41) 0.9
1975-1979 242886 15 1.2 (0.69-2.04) 1.5
1980-1984 244614 57 4.7 (3.53-6.04) 5.3
1985-1989 241266 60 5.0 (3.80-6.40) 5.4
1990-1994 239953 63 5.3 (4.04-6.72) 5.4
1995-1999 240131 86 7.2 (5.73-8.85) 7.3
2000-2004 237783 88 7.4 (5.94-9.12) 7.6
2005-2009 235779 119 10.1 (8.36-12.98) 10.7
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(Table 6). Data from other high prevalence areas have
also shown sex ratio stability over time [6,28], but across
the world there has been an increase in the ratio [29].
For instance, a Canadian study of 27074 patients showed
that the f/m ratio by year of birth increased over a
period of at least 50 years [30]. In a Danish prevalence
study including 9377 patients the f/m ratio increased
from 1.31 in 1950 to 2.02 in 2005 [31]. A Swedish study
including 8834 patients from the national MS patient
registry did not find evidence for an increased f/m ratio
by year of birth among MS patients born between 1931
and 1985 [32]. However, when the study was expanded
to 19510 patients by including information from add-
itional registers an increased sex ratio was identified.
The f/m ratio was 1.70 among patients born 1931–1935,
and increased to 2.67 among those borne 1981–1985
[33]. More than twice as many women than men have
MS in Nordland, but as said this has been unchanged
over the last decades. The data from our region is quite
complete when it comes to registered patients in the
given period, but we cannot exclude that the material is
too small to demonstrate a trend.
We calculated the distribution of RRMS and PPMS both
in the prevalence and the incidence numbers (Tables 3
and 7). We find a PPMS course of disease at onset inTable 5 Age at diagnosis and time from first symptom to dia
Age at onset, year Time from
Years Mean (SD) Range Mean (SD
1970-1974 42.2 (8.7) 30-52 7.7 (5.9)
1975-1979 38.6 (10.5) 22-61 4.3 (5.3)
1980-1984 38.9 (11.8) 21-70 6.0 (7.9)
1985-1989 38.3 (11.1) 14-64 4.2 (5.9)
1990-1994 36.9 (10.4) 18-66 5.2 (6.5)
1995-1999 39.3 (10.0) 18-69 4.9 (5.6)
2000-2004 40.4 (11.4) 12-75 5.0 (6.1)
2005-2009 40.4 (11.0) 14-71 5.0 (6.1)18.6% of the prevalence at January 1, 2010. This is higher
than other Norwegian studies performed after 2000, which
find the proportion of PPMS ranging from 9.3 to 16.8%
[12,13]. In a study from Finland, the proportion of PPMS
was 22% in the period 1979–1993 [34]. We find that the
proportion of PPMS has steadily decreased in the preva-
lence numbers from 1980 to 2010. However, the propor-
tion of PPMS in the incidence numbers have been quite
stable at approximately 20% from 1990–1994.
Findings from previous studies indicate a relatively low
occurrence of MS in Troms and Finnmark, the two most
northern counties of Norway, with a prevalence of 73.0
per 100 000 in 1993 [10]. The Sami is considered the trad-
itionally indigenous inhabitants in northern Norway,
Sweden, Finland and northwest Russia. It is a low preva-
lence of MS in the Sami population [19]. The majority
lives in Finnmark, but there is no exact statistical data on
the Norwegian Sami population. It is estimated that about
40 000 Sami are living in the country, of those are about
30 000 living north of the Arctic Circle. A clue about the
distribution of the Sami population is the figures of the
members in the Sami electoral register, in which member-
ship is voluntary. At June 30, 2009 there were 13 890 per-
sons registered in the Sami electoral register. In Nordland
1190 persons were registered. In Troms, with 156 494 in-
habitants at 01.01.2010, 2807 persons were registered,gnosis
first symptom to diagnosis, years









Table 6 Gender specific incidence
Women Men F/M sex ratio
Years Cases Incidence Cases Incidence
1970-1974 8 1.4 1 0.2 7.0
1975-1979 10 1.7 5 0.8 2.1
1980-1984 34 5.6 23 3.7 1.5
1985-1989 41 6.8 19 3.1 2.2
1990-1994 38 6.4 25 4.2 1.5
1995-1999 59 9.8 27 4.5 2.2
2000-2004 57 9.6 31 5.2 1.8
2005-2009 82 13.9 37 6.2 2.2
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7432 persons were registered in the electoral register. The
high proportion of Sami could thus, at least to some ex-
tent, count for the low prevalence of MS in Troms and
Finnmark compared to Nordland.
When prevalence and incidence rates are compared
from different regions, it must be noticed that the surveys
are from different times. The incidence and prevalence are
in general increasing, and older studies will show lover oc-
currence than newer. The prevalence data from Troms
and Finnmark are from 1993. The prevalence reported is
lower than the prevalence in Nordland in 2000, but higher
than the prevalence in Nordland in 1990. Nevertheless,
from the same period (1995) the prevalence is much
higher in Oslo to the south in the country. The present
study is one of the two newest epidemiological studies in
Norway, the other is from Vest-Agder to the very south.
The prevalence in Nordland in 2010 is quite equal to that
in Vest-Agder in 2007. It therefore seems to be a tendency
towards a more homogeneous distribution of the disease
in Norway. There are indications of dispersion of MS in
Sweden. This change of distribution over time indicates
that genetic background is not the only explanation of the
origin of the disease [35].
There are certain strengths in our study that need to be
pointed out. Our study has a long time span in a regionTable 7 Distribution of the incidence of PPMS and RRMS
course at onset
Years PPMS, % (n) RRMS, % (n) Unknown, % (n)
1970-1974 33.3 (3) 55.6 (5) 11.1 (1)
1975-1979 33.3 (5) 66.7 (10) 0 (0)
1980-1984 28.8 (13) 70.2 (40) 7.0 (4)
1985-1989 26.7 (16) 66.7 (40) 6.7 (4)
1990-1994 20.6 (13) 77.8 (49) 1.6 (1)
1995-1999 17.4 (15) 82.6 (71) 0 (0)
2000-2004 19.3 (17) 79.5 (70) 1.1 (1)
2005-2009 21.8 (26) 78.2 (93) 0 (0)with a relatively homogenous and stable population.
Norway has a well-developed public healthcare, and it is
likely that a person with symptoms of MS nowadays will
have a prompt medical examination. In Nordland County,
all patients with MS are treated by a neurologist employed
by a public hospital. This suggests that the number of
cases of MS from a hospital based survey, is very close to
the real number in the population. In the present study,
all medical files were re-evaluated by a neurologist to con-
firm the diagnosis. There are, however, some limitations.
In the days when the diagnosis was made without the help
of MRI, the diagnosis was more uncertain. Patients with
mimicking symptoms could wrongly be diagnosed with
MS, giving higher estimate of the occurrence. On the
other hand, it is likely that the threshold to seek medical
help has decreased in parallel to an increasing supply of
health service, implying that benign MS and other light
symptoms earlier could have been easily ignored both by
the patient and the doctor giving a lower estimate of the
prevalence.
Conclusion
The occurrence of MS in Nordland County has been
continuously increasing both in terms of prevalence and
incidence over a period of 40 years. On January 1, 2010
the prevalence was 182.4 per 100 000. In the period
2005–2009 the average yearly incidence was 10.1 per
100 000. Nordland County is a high risk area for MS.
Previous findings indicating a paradoxically low preva-
lence in the north of Norway could not be confirmed.
Although the prevalence and incidence are higher
among women then among men, we did not find an in-
creased female to male ratio over time.
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